Lifileucel + LN-145 + Pembrolizumab + LN-145-S1 + Ipilimumab + Nivolumab + Nivolumab-relatlimab + Cisplatin + Carboplatin + Paclitaxel + Nab-Paclitaxel + Pemetrexed
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Melanoma
Conditions
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
Trial Timeline
May 7, 2019 → Aug 9, 2029
NCT ID
NCT03645928About Lifileucel + LN-145 + Pembrolizumab + LN-145-S1 + Ipilimumab + Nivolumab + Nivolumab-relatlimab + Cisplatin + Carboplatin + Paclitaxel + Nab-Paclitaxel + Pemetrexed
Lifileucel + LN-145 + Pembrolizumab + LN-145-S1 + Ipilimumab + Nivolumab + Nivolumab-relatlimab + Cisplatin + Carboplatin + Paclitaxel + Nab-Paclitaxel + Pemetrexed is a phase 2 stage product being developed by Iovance Biotherapeutics for Metastatic Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03645928. Target conditions include Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03645928 | Phase 2 | Recruiting |
Competing Products
20 competing products in Metastatic Melanoma